The Warburg Effect: Why Cancer Cells Ferment Glucose
Nearly a century ago Otto Warburg observed that cancer cells consume glucose at high rates and secrete lactate even when oxygen is plentiful, rather than fully oxidising glucose in mitochondria. This aerobic glycolysis, the Warburg effect, is a common feature of proliferating cells and has practical consequences.
Quick Answer
Nearly a century ago Otto Warburg observed that cancer cells consume glucose at high rates and secrete lactate even when oxygen is plentiful, rather than fully oxidising glucose in mitochondria. This aerobic glycolysis, the Warburg effect, is a common feature of proliferating cells and has practical consequences.
Part of a topic cluster
Immuno-Oncology and Tumour Metabolism
Open the complete 15-article guideNot About Broken Mitochondria
Warburg originally proposed that cancer cells had damaged respiration. In fact most tumour cells have functional mitochondria and use them. The shift toward glycolysis is a regulated choice driven by growth signalling, not a defect.
Oncogenic pathways including PI3K/AKT, MYC and HIF-1 directly increase glucose transporters and glycolytic enzymes, linking the metabolic phenotype to the same drivers that push proliferation.
Why It Makes Sense for a Growing Cell
A dividing cell needs carbon and nitrogen building blocks more than it needs maximal energy. Running glucose through glycolysis quickly, and diverting intermediates into the pentose phosphate pathway and into serine, lipid and nucleotide synthesis, supplies biosynthesis and maintains the redox cofactors needed for it.
Lactate secretion regenerates the NAD+ required to keep glycolysis running fast, and the exported lactate and protons also acidify the microenvironment in ways that can impair immune cells.
Clinical Footprint
The high glucose uptake of many tumours is the basis of FDG-PET imaging, which uses a radiolabelled glucose analogue to locate metabolically active disease. Tumours with a weak Warburg phenotype, such as some low-grade or mucinous cancers, are less FDG-avid.
Drugs directly targeting glycolysis have been difficult to develop because normal proliferating cells share the pathway, so most metabolic strategies target more tumour-selective dependencies.
What the Metabolism Can and Cannot Be Used For
The reliable clinical use of the Warburg phenotype is imaging. FDG-PET stages many cancers, assesses treatment response and detects recurrence, and its limitations follow directly from the biology — brain, kidney and inflamed tissue are FDG-avid for other reasons, and weakly glycolytic tumours can be falsely reassuring.
As a drug target the pathway has been frustrating. Lactate-transporter and lactate-dehydrogenase inhibitors and other glycolysis-directed agents remain investigational, and most metabolic drug development has moved toward more selective dependencies such as mutant IDH, glutaminase in specific contexts, or MTAP-deletion-linked PRMT5.
Key Takeaways
- ·The Warburg effect is high glucose uptake with lactate production despite available oxygen.
- ·It reflects regulated support of biosynthesis and redox balance, not damaged mitochondria.
- ·It underlies FDG-PET imaging and contributes to an acidic, immunosuppressive microenvironment.
Put these genes in pathway context
Frequently asked questions
Does the Warburg effect mean cancer cells have broken mitochondria?
No. Most tumour cells have functional mitochondria and use them; the shift toward glycolysis is a regulated response to growth signalling, driven by pathways such as PI3K/AKT, MYC and HIF-1.
How does the Warburg effect relate to PET scans?
FDG-PET uses a radiolabelled glucose analogue, and the high glucose uptake of many tumours makes them light up. Tumours with a weak Warburg phenotype, such as some low-grade or mucinous cancers, are less FDG-avid.
Why is glycolysis hard to target with drugs?
Normal proliferating cells use the same pathway, so blocking it broadly is toxic; most metabolic strategies target more tumour-selective dependencies instead.
References
Continue Reading
Glutamine Metabolism in Cancer
3 min read
HIF-1α and Tumour Hypoxia: A Signalling Guide
2 min read
The Adenosine Pathway: CD39, CD73 and A2A Receptors
3 min read
The PI3K/AKT/mTOR Pathway in Cancer
4 min read
STAT3 Signalling in Cancer: The IL-6/JAK/STAT3 Axis
3 min read
BCL2 Family Proteins and Cancer Cell Survival
5 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
MYC has 40+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.